←
Dr. Estela Rodriguez14,875 posts
Dr. Estela Rodriguez avatar

Dr. Estela Rodriguez

@Latinamd

Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed

◷ Joined June 2012▧ 5,353 Photos and videos
International Lung Cancer Summit avatar
⟳ Dr. Estela Rodriguez retweeted
International Lung Cancer Summit@LungSummit·Nov 17

A trial built to pre-empt small cell transformation in TP53/RB1-deficient, EGFR-mutant NSCLC still saw it in nearly half of its patients. The paper, led by Lena Morrill Gavarró and Helena Alexandra Yu, includes our faculty member Charles Rudin (@charlesrudin) among its authors. 🔬 Prospective trial: 1L osimertinib plus platinum and etoposide in EGFR-mutant, TP53/RB1-deficient NSCLC 📊 SCLC transformation in 5 of 11 patients despite SCLC-directed chemotherapy 📊 mPFS 11 mo; mOS 33 mo 📌 Profiling also found mesenchymal and squamous histologies, tied to progressive RB pathway disruption ⚠️ 11 patients and 1 arm, so no comparison with osimertinib alone Find the single-cell findings on mesenchymal and squamous change in our article. lungsummit.org/articles/sclc…

Post attachment
Dr. Estela Rodriguez avatar
Dr. Estela Rodriguez@Latinamd·14h

A great way to celebrate #LCAM26! 🎉 @FDA accelerated approval of #Neladalkib (Nelkarmi) for previously treated ALK+ advanced NSCLC marks another milestone in two decades of progress—and more hope for our patients. 🫁 ▶️ ALKOVE-1: ORR 49% post-alectinib; 32% after ≥2 ALK TKIs + platinum. 🎯 Durable responses: ≥12-month DOR in ~half of responders. 🧠 Promising CNS activity. ⚠️ Key AEs: transaminase elevations, GI effects, myalgias and edema. An important new salvage option for ALK+ lung cancer, including patients with CNS disease. #LCSM #ALK @ALKPositiveinc @ALKpositiveINT

Post attachment
Dr. Estela Rodriguez avatar
Dr. Estela Rodriguez@Latinamd·15h

😱 Fascinated and disturbed by this @NEJM_AI analysis where the authors estimate that Heme-Onc speciality work is only 15% Physical and not substitutable by software/AI. - Can I treat patients w cancer remotely with AI- assisted software? Yes - but is it right? - Are we moving to a future where patients will be discussing hospice and goals of care, side effects management w machines and not actual doctors? #MedTwitter #AI

The authors analyze the degree to which clinical specialties are shielded from, or threatened by, AI depending on how much of their work requires in-person physical interaction. Learn more: nejm.ai/3UDkrIv

Post attachment
View quoted post ↗
Dr. Estela Rodriguez avatar
Dr. Estela Rodriguez@Latinamd·21h

#LCAM26 Every one of these patients has felt the stigma of lung cancer. Every one was told they had incurable cancer at diagnosis. They carry the weight of those words, and so do their families. This month, I remember their pain, their courage, and the importance of replacing stigma with compassion. No one deserves lung cancer. Every patient with #lungcancer deserves dignity, support and access to treatment #LCAM26 #LungCancerAwareness #LCSM

Post attachment
Dr. Estela Rodriguez avatar
Dr. Estela Rodriguez@Latinamd·Nov 17

It’s been a weird week. Planes grounded, Outlook down, and now @FDA declines to approve @SMMT_TX ivonescimab for EGFR-mutant lung cancer after osimertinib resistance (HARMONi trial). Despite a meaningful PFS benefit, lack of demonstrated OS benefit was the deciding factor — a challenging standard, particularly when other cancer drugs have been approved with similar PFS/OS discrepancies in this space 🤷🏽‍♀️ reuters.com/legal/litigation…

Giannis Mountzios avatar
⟳ Dr. Estela Rodriguez retweeted
Giannis Mountzios@g_mountzios·Nov 15

FDA declines approval of Ivonescimab for 2L #EGFRmut #NSCLC with chemo due to lack of OS benefit despite the PFS benefit. Important decision marking a shift in strategy? Chemo+ ami and Dato-DXd got approval in the same setting based on PFS, Should OS be the golden endpoint for 2L approvals ? reuters.com/legal/litigation…

Dr. Estela Rodriguez avatar
Dr. Estela Rodriguez@Latinamd·Nov 16

Here we go again… putting up the Christmas tree 🌲 and trying to keep the cats from climbing it. Or maybe my cat is just looking for shelter before the next global communications shutdown. 😂 #CatsOfX

Post attachment
Alessio Cortellini avatar
⟳ Dr. Estela Rodriguez retweeted
Alessio Cortellini@ACortelliniMD·Nov 15

November is Lung Cancer Awareness Month! Lung cancer is one of the fields in oncology where research and clinical trials are moving at an extraordinary pace. Yet, the gap between scientific innovation and its implementation in everyday clinical practice is growing. For me, lung cancer awareness also means recognising this gap, because progress only matters if it reaches patients, globally. Glad to contribute to #LCAM2026 as a member of the @IASLC Communications Committee. @Latinamd @MattSmeltzer @CharuAggarwalMD @herbloong @ADesaiMD @lungoncdoc @StephenVLiu @NarjustFlorezMD @DrJNaidoo @ReckampK #LungCancerAwarenessMonth #IASLC

Post attachment
ALCSI avatar
⟳ Dr. Estela Rodriguez retweeted
ALCSI@AmLungCSI·Nov 16

🏳️🫁 Every Breath Forward Flag Planting Event: University of Illinois-Chicago The University of Illinois-Chicago ALCSI chapter joined @LUNGevity's Every Breath Forward campaign with an incredible white flag planting event in Chicago, IL! The team partnered with the nurses and the UI screening center to plant 5,000 white flags honoring lives lost to lung cancer, raising awareness about screening eligibility and the importance of early detection! This is a powerful display of community, collaboration, and commitment to expanding access to lifesaving lung cancer screening!!! 🙌💙 #LungCancerAwareness #ScreeningSavesLives #ALCSI #UICALCSI #EveryBreathForward #LCAM @thisisUIC

0:36
Dr. Estela Rodriguez avatar
Dr. Estela Rodriguez@Latinamd·Nov 16

Glad that @ABIMcert continues to report the diversity of newly certified Medical Oncology diplomates in its 2026 Annual Report. But it’s disappointing to see how little progress we’ve made over time. Still, only 6% of Med Onc diplomates identify as Latino and 4% as Black. #Diversitymatters. #Representationmatters. We need sustained investment in early STEM education, mentorship, and pathways into medicine and oncology to build a more diverse future workforce. Source: ABIM 2026 Annual Report. @LatinxOncology

Post attachment
Dr. Estela Rodriguez avatar
Dr. Estela Rodriguez@Latinamd·Nov 14

#LALCA26 @IASLC 🇧🇷 Simon Bolivar said it best: “In the unity of our nations rests the glorious future of our peoples.” Obrigada to the #LATAM26 CoChairs @clarissamathias and Dr William William🇧🇷 , for the opportunity to spend time with so many amazing thoracic oncologists, researchers, and patient advocates. Grateful for the knowledge shared, the meaningful conversations, and our collective commitment to advancing research and improving patient care across Latin America. 🫁❤️ #LATAM #GlobalOnc #LungCancer

Post attachmentPost attachmentPost attachmentPost attachment
Dr. Estela Rodriguez avatar
Dr. Estela Rodriguez@Latinamd·Nov 14

#LATAM26 @IASLC 🇧🇷 Excited to be part of this panel discussing the new frontiers of bispecific antibodies and antibody-drug conjugates (ADCs) in lung cancer—with and without actionable mutations. Beyond efficacy, we need to tackle toxicity management, optimal sequencing, and, most importantly, a critical question: What is the added value 💲 of these innovative therapies in resource-constrained settings❓ Innovation must translate into meaningful, accessible patient benefit across Latin America and beyond. 🌎🫁 #LCSM #GlobalOnc @SylvesterCancer

Post attachmentPost attachment